Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07QXU
|
|||
| Former ID |
DCL000900
|
|||
| Drug Name |
NS 2359
|
|||
| Synonyms |
FPTPUYCHSWIWIB-FUTJPDQTSA-N; SCHEMBL2640060; (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo-[321]octane; GSK372475
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cocaine addiction [ICD-11: 6C45.2; ICD-10: F14.2; ICD-9: 304.2] | Phase 2 | [1] | |
| Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] | Discontinued in Phase 2 | [2] | ||
| Mood disorder [ICD-11: 6A60-6E23] | Discontinued in Phase 2 | [3] | ||
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H21Cl2NO
|
|||
| Canonical SMILES |
CN1C2CCC1C(C(C2)C3=CC(=C(C=C3)Cl)Cl)COC
|
|||
| InChI |
1S/C16H21Cl2NO/c1-19-11-4-6-16(19)13(9-20-2)12(8-11)10-3-5-14(17)15(18)7-10/h3,5,7,11-13,16H,4,6,8-9H2,1-2H3/t11-,12+,13+,16+/m0/s1
|
|||
| InChIKey |
PGYDXVBZYKQYCS-VPWBDBDCSA-N
|
|||
| CAS Number |
CAS 195875-68-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. | |||
| REF 3 | Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder. Drug Des Devel Ther. 2014 Dec 1;8:2321-32. | |||
| REF 4 | Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.